A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients (PILCHARDUS)
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Sardine diet
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Diet, Sardine, Type 2 diabetes
Eligibility Criteria
Inclusion Criteria:
- Age > 40 years and < 85
- BMI ≥ 25 and < 35
- Patients diagnosed with type 2 diabetes at onset or treated only by diet
- HbA1c between 6.0 and 8.0% (based on the last measured and documented laboratory measurement of the previous 3 months)
- Usual consumption ≤ 3 fish per week
Exclusion Criteria:
- T2D treated with antidiabetic oral drugs and/or insulin
- Current or previous (within 3 months) intake of omega 3 suplements
- Known allergy or intolerance to fish or fish protein
- Diagnosis of active neoplasic disease
- Suffering from an acute illness which requires a recovery period higher than one week
- Currently chronic treatment with oral steroids or nonesteroidal anti-inflammatory for more than 5 days, at least 1 month before randomization
- Pregnant or breast-feeding patients
- Serious acute vascular events (cardiac or cerebral) diagnosed previous 2 months before the randomization
- Current or previous (within 6 months) participation in another study
- Chronic renal insufficiency (creatinine >1,5 mg/dl)
- Any conditions that the investigator considers may render the patient unable to complete the study
During the interventional study, based on current standards of T2D care, doctors will introduce anti-diabetic oral drugs or insulin into the patient's treatment, where they consider it to be necessary.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Sardine diet
Control diet
Arm Description
Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.
Subjects only follow general dietary recommendations for diabetes.
Outcomes
Primary Outcome Measures
Change from baseline in glycated hemoglobin (HbA1c) at 6 months
Change from baseline in fasting glucose at 6 months
Change from baseline in fasting insulin at 6 months
Secondary Outcome Measures
Change from baseline in adiponectin at 6 months
Change from baseline in leptin at 6 months
Change from baseline in ultra sensitive C-reactive protein (us-CRP) at 6 months
Change from baseline in interleukin-6 (IL-6) at 6 months
Change from baseline in interleukin-8 (IL-8) at 6 months
Change from baseline in interleukin-10 (IL-10) at 6 months
Change from baseline in tumor necrosis factor alpha (TNFα) at 6 months
Change from baseline in erytrocite membrane fatty acid composition (EMFA) at 6 months
Change from baseline in specific bacterial groups of gut microbiota at 6 months
Change from baseline in total cholesterol at 6 months
Change from baseline in LDL cholesterol at 6 months
Change from baseline in HDL cholesterol at 6 months
Change from baseline in triglycerides at 6 months
Change from baseline in blood pressure at 6 months
Full Information
NCT ID
NCT02294526
First Posted
October 31, 2014
Last Updated
January 28, 2015
Sponsor
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
1. Study Identification
Unique Protocol Identification Number
NCT02294526
Brief Title
A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients
Acronym
PILCHARDUS
Official Title
PILCHARDUS STUDY: A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients
Study Type
Interventional
2. Study Status
Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
November 2012 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
November 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Work hypothesis
A diet rich in sardine will improve the metabolic control in type 2 diabetes patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Diet, Sardine, Type 2 diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
35 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sardine diet
Arm Type
Experimental
Arm Description
Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.
Arm Title
Control diet
Arm Type
No Intervention
Arm Description
Subjects only follow general dietary recommendations for diabetes.
Intervention Type
Other
Intervention Name(s)
Sardine diet
Intervention Description
Diet rich in sardine: 100g/day of sardine 5 times a week
Primary Outcome Measure Information:
Title
Change from baseline in glycated hemoglobin (HbA1c) at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in fasting glucose at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in fasting insulin at 6 months
Time Frame
Baseline and 6 months
Secondary Outcome Measure Information:
Title
Change from baseline in adiponectin at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in leptin at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in ultra sensitive C-reactive protein (us-CRP) at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in interleukin-6 (IL-6) at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in interleukin-8 (IL-8) at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in interleukin-10 (IL-10) at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in tumor necrosis factor alpha (TNFα) at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in erytrocite membrane fatty acid composition (EMFA) at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in specific bacterial groups of gut microbiota at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in total cholesterol at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in LDL cholesterol at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in HDL cholesterol at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in triglycerides at 6 months
Time Frame
Baseline and 6 months
Title
Change from baseline in blood pressure at 6 months
Time Frame
Baseline and 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 40 years and < 85
BMI ≥ 25 and < 35
Patients diagnosed with type 2 diabetes at onset or treated only by diet
HbA1c between 6.0 and 8.0% (based on the last measured and documented laboratory measurement of the previous 3 months)
Usual consumption ≤ 3 fish per week
Exclusion Criteria:
T2D treated with antidiabetic oral drugs and/or insulin
Current or previous (within 3 months) intake of omega 3 suplements
Known allergy or intolerance to fish or fish protein
Diagnosis of active neoplasic disease
Suffering from an acute illness which requires a recovery period higher than one week
Currently chronic treatment with oral steroids or nonesteroidal anti-inflammatory for more than 5 days, at least 1 month before randomization
Pregnant or breast-feeding patients
Serious acute vascular events (cardiac or cerebral) diagnosed previous 2 months before the randomization
Current or previous (within 6 months) participation in another study
Chronic renal insufficiency (creatinine >1,5 mg/dl)
Any conditions that the investigator considers may render the patient unable to complete the study
During the interventional study, based on current standards of T2D care, doctors will introduce anti-diabetic oral drugs or insulin into the patient's treatment, where they consider it to be necessary.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ramon Gomis, Professor
Organizational Affiliation
CIBERDEM - IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer) - Hospital Clínic of Barcelona
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
27090218
Citation
Balfego M, Canivell S, Hanzu FA, Sala-Vila A, Martinez-Medina M, Murillo S, Mur T, Ruano EG, Linares F, Porras N, Valladares S, Fontalba M, Roura E, Novials A, Hernandez C, Aranda G, Siso-Almirall A, Rojo-Martinez G, Simo R, Gomis R. Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naive patients with type 2 diabetes: a pilot randomized trial. Lipids Health Dis. 2016 Apr 18;15:78. doi: 10.1186/s12944-016-0245-0.
Results Reference
derived
Learn more about this trial
A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients
We'll reach out to this number within 24 hrs